
Berend J Slotman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7134448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung – The Knockout Punch. Clinical Oncology, 2022, 34, e183-e194.	1.4	12
2	Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. Lung Cancer, 2022, 170, 185-193.	2.0	4
3	Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. European Urology Oncology, 2021, 4, 628-634.	5.4	46
4	American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology, 2021, 16, 54-65.	1.1	13
5	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. Radiotherapy and Oncology, 2021, 154, 269-273.	0.6	11
6	Experimental and clinical studies on radiation and curcumin in human glioma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 403-409.	2.5	9
7	Investigating the potential of deep learning for patient-specific quality assurance of salivary gland contours using EORTC-1219-DAHANCA-29 clinical trial data. Acta Oncológica, 2021, 60, 575-581.	1.8	5
8	Using Spatial Probability Maps to Highlight Potential Inaccuracies in Deep Learning-Based Contours: Facilitating Online Adaptive Radiation Therapy. Advances in Radiation Oncology, 2021, 6, 100658.	1.2	9
9	Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer. Radiotherapy and Oncology, 2021, 157, 197-202.	0.6	12
10	Ultra-High Dose Rate Transmission Beam Proton Therapy for Conventionally Fractionated Head and Neck Cancer: Treatment Planning and Dose Rate Distributions. Cancers, 2021, 13, 1859.	3.7	22
11	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 161.	8.6	16
12	European radiation oncology after one year of COVID-19 pandemic. Clinical and Translational Radiation Oncology, 2021, 28, 141-143.	1.7	11
13	Markerless Real-Time 3-Dimensional kV Tracking of Lung Tumors During Free Breathing Stereotactic Radiation Therapy. Advances in Radiation Oncology, 2021, 6, 100705.	1.2	12
14	Editorial: Online Adaptive MR-Guided Radiotherapy. Frontiers in Oncology, 2021, 11, 748685.	2.8	7
15	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical Lung Cancer, 2021, 22, 579-586.	2.6	9
16	Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases. Physics and Imaging in Radiation Oncology, 2021, 20, 1-4.	2.9	1
17	Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy. Radiotherapy and Oncology, 2021, 163, 14-20.	0.6	10
18	Markerless 3D tumor tracking during single-fraction free-breathing 10MV flattening-filter-free stereotactic lung radiotherapy. Radiotherapy and Oncology, 2021, 164, 6-12.	0.6	8

#	Article	IF	CITATIONS
19	Relationship between Treatment Plan Dosimetry, Toxicity, and Survival following Intensity-Modulated Radiotherapy, with or without Chemotherapy, for Stage III Inoperable Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5923.	3.7	3
20	Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. Radiotherapy and Oncology, 2020, 144, 46-52.	0.6	64
21	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. JAMA Oncology, 2020, 6, 567.	7.1	64
22	Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma. Journal of Neuro-Oncology, 2020, 146, 239-246.	2.9	21
23	Assessing the Variability and Quality of Lung Stereotactic Radiation Therapy Treatment Plans Using a Web-Based Crowdsourcing Platform. Practical Radiation Oncology, 2020, 10, e118-e127.	2.1	5
24	The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. Radiotherapy and Oncology, 2020, 145, 45-48.	0.6	9
25	Bringing FLASH to the Clinic: Treatment Planning Considerations for Ultrahigh Dose-Rate Proton Beams. International Journal of Radiation Oncology Biology Physics, 2020, 106, 621-629.	0.8	87
26	The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer. Cancers, 2020, 12, 2763.	3.7	30
27	Changes in gastric anatomy after delivery of breath-hold MR-guided SABR for adrenal metastases. Radiotherapy and Oncology, 2020, 152, 26-29.	0.6	7
28	Stereotactic radiosurgery (SRS) – A new normal for small cell lung cancer?. Clinical and Translational Radiation Oncology, 2020, 25, 10-15.	1.7	3
29	Is the introduction of more advanced radiotherapy techniques for locally-advanced head and neck cancer associated with improved quality of life and reduced symptom burden?. Radiotherapy and Oncology, 2020, 151, 298-303.	0.6	8
30	Initial Impact and Operational Responses to the COVID-19 Pandemic by American Radiation Oncology Practices. International Journal of Radiation Oncology Biology Physics, 2020, 108, 356-361.	0.8	26
31	Strategies to improve deep learning-based salivary gland segmentation. Radiation Oncology, 2020, 15, 272.	2.7	6
32	A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. Nature Communications, 2020, 11, 2935.	12.8	57
33	Image guidance in radiation therapy for better cure of cancer. Molecular Oncology, 2020, 14, 1470-1491.	4.6	63
34	Effect of COVID-19 pandemic on practice in European radiation oncology centers. Radiotherapy and Oncology, 2020, 150, 40-42.	0.6	53
35	Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2020, 107, 270-278.	0.8	71
36	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.8	40

#	Article	IF	CITATIONS
37	In Reply to Moeckli etÂal. International Journal of Radiation Oncology Biology Physics, 2020, 107, 1013-1014.	0.8	0
38	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiotherapy and Oncology, 2020, 152, 89-95.	0.6	23
39	Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy. Physics and Imaging in Radiation Oncology, 2020, 14, 17-23.	2.9	61
40	Examining geographic accessibility to radiotherapy in Canada and Greenland for indigenous populations: Measuring inequities to inform solutions. Radiotherapy and Oncology, 2020, 146, 1-8.	0.6	12
41	Cardiac radioablation—A systematic review. Heart Rhythm, 2020, 17, 1381-1392.	0.7	94
42	Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2020, 10, 158-173.	2.1	111
43	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.6	168
44	Development of transient radioresistance during fractionated irradiation in vitro. Radiotherapy and Oncology, 2020, 148, 107-114.	0.6	12
45	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer – Decision criteria in routine practise. Radiotherapy and Oncology, 2020, 150, 26-29.	0.6	13
46	What is the role of consolidative thoracic radiotherapy in the era of chemo-immunotherapy for extensive stage small cell lung cancer?. Journal of Thoracic Disease, 2020, 12, 6308-6310.	1.4	1
47	What is the role of consolidative thoracic radiotherapy in the era of chemo-immunotherapy for extensive stage small cell lung cancer?. Journal of Thoracic Disease, 2020, 12, 6308-6310.	1.4	6
48	Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 2019, 19, 816.	2.6	165
49	Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 1219.	2.8	27
50	A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1086-1094.	0.8	127
51	End-to-end empirical validation of dose accumulation in MRI-guided adaptive radiotherapy for prostate cancer using an anthropomorphic deformable pelvis phantom. Radiotherapy and Oncology, 2019, 141, 200-207.	0.6	24
52	Access to radiotherapy and its association with cancer outcomes in a high-income country: Addressing the inequity in Canada. Radiotherapy and Oncology, 2019, 141, 48-55.	0.6	21
53	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 133, 163-166.	0.6	24
54	Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2019, 104, 933-941.	0.8	75

#	Article	IF	CITATIONS
55	Deep Learning-Based Delineation of Head and Neck Organs at Risk: Geometric and Dosimetric Evaluation. International Journal of Radiation Oncology Biology Physics, 2019, 104, 677-684.	0.8	83
56	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 135, 74-77.	0.6	14
57	Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer. Physics and Imaging in Radiation Oncology, 2019, 9, 69-76.	2.9	128
58	Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5Ãcm. International Journal of Radiation Oncology Biology Physics, 2019, 103, 259-267.	0.8	13
59	Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. Radiotherapy and Oncology, 2019, 132, 16-22.	0.6	37
60	Summarizing the 4D image stack of ultrafast dynamic contrast enhancement MRI of breast cancer in 3D using color intensity projections. Journal of Magnetic Resonance Imaging, 2019, 49, 1391-1399.	3.4	8
61	Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance. Radiotherapy and Oncology, 2019, 130, 75-81.	0.6	24
62	Stereotactic radiosurgery for tremor: systematic review. Journal of Neurosurgery, 2019, 130, 589-600.	1.6	27
63	Stereotactic radiosurgery for trigeminal neuralgia: a systematic review. Journal of Neurosurgery, 2019, 130, 733-757.	1.6	109
64	Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017. Journal of Thoracic Oncology, 2018, 13, 488-496.	1.1	10
65	Personalized automated treatment planning for breast plus locoregional lymph nodes using Hybrid RapidArc. Practical Radiation Oncology, 2018, 8, 332-341.	2.1	26
66	Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline. Neurosurgery, 2018, 83, 345-353.	1.1	64
67	First Experience With Markerless Online 3D Spine Position Monitoring During SBRT Delivery Using a Conventional LINAC. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1253-1258.	0.8	15
68	Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay. Journal of Thoracic Oncology, 2018, 13, 855-862.	1.1	18
69	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2018, 127, 1-5.	0.6	141
70	Is accurate contouring of salivary and swallowing structures necessary to spare them in head and neck VMAT plans?. Radiotherapy and Oncology, 2018, 127, 190-196.	0.6	16
71	Stereotactic Radiosurgery for Benign (World Health Organization Grade I) Cavernous Sinus Meningiomas—International Stereotactic Radiosurgery Society (ISRS) Practice Guideline. Neurosurgery, 2018, 83, 1128-1142.	1.1	42
72	Using 3D printing techniques to create an anthropomorphic thorax phantom for medical imaging purposes. Medical Physics, 2018, 45, 92-100.	3.0	97

#	Article	IF	CITATIONS
73	Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. Molecular Cancer Therapeutics, 2018, 17, 347-354.	4.1	22
74	Radiation Oncology in The Netherlands. International Journal of Radiation Oncology Biology Physics, 2018, 100, 5-11.	0.8	2
75	The evolving role of radiotherapy in the management of small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S2545-S2554.	1.4	6
76	Automated Knowledge-Based Intensity-Modulated Proton Planning: An International Multicenter Benchmarking Study. Cancers, 2018, 10, 420.	3.7	21
77	Radiation Therapy for Small-Cell Lung Cancer. , 2018, , 1-7.		0
78	Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice. Cancer Treatment and Research Communications, 2018, 17, 18-22.	1.7	3
79	Feasibility of markerless 3D position monitoring of the central airways using kilovoltage projection images: Managing the risks of central lung stereotactic radiotherapy. Radiotherapy and Oncology, 2018, 129, 234-241.	0.6	10
80	MR-guided Gated Stereotactic Radiation Therapy Delivery for Lung, Adrenal, and Pancreatic Tumors: A Geometric Analysis. International Journal of Radiation Oncology Biology Physics, 2018, 102, 858-866.	0.8	118
81	Markerless positional verification using template matching and triangulation of kV images acquired during irradiation for lung tumors treated in breath-hold. Physics in Medicine and Biology, 2018, 63, 115005.	3.0	24
82	Toward planning target volume margin reduction for the prostate using intrafraction motion correction with online kV imaging and automatic detection of implanted gold seeds. Practical Radiation Oncology, 2018, 8, 422-428.	2.1	18
83	Patient-reported Outcome Measurements on the Tolerance of Magnetic Resonance Imaging-guided Radiation Therapy. Cureus, 2018, 10, e2236.	0.5	29
84	Evaluation of an Automated Proton Planning Solution. Cureus, 2018, 10, e3696.	0.5	15
85	Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. Radiotherapy and Oncology, 2017, 122, 411-415.	0.6	18
86	What is the optimal radiotherapy schedule for limited stage small cell lung cancer?. Lung Cancer, 2017, 105, 52-53.	2.0	6
87	Knowledge-based planning for stereotactic radiotherapy of peripheral early-stage lung cancer. Acta Oncológica, 2017, 56, 490-495.	1.8	14
88	Analysis of components of variance determining probability of setup errors in CBCTâ€guided stereotactic radiotherapy of lung tumors. Medical Physics, 2017, 44, 382-388.	3.0	6
89	Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy. Acta Oncológica, 2017, 56, 548-554.	1.8	14
90	Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. Clinical Genitourinary Cancer, 2017, 15, e773-e782.	1.9	33

#	Article	IF	CITATIONS
91	Using a knowledge-based planning solution to select patients for proton therapy. Radiotherapy and Oncology, 2017, 124, 263-270.	0.6	40
92	Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer, 2017, 108, 150-153.	2.0	70
93	Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?. Seminars in Radiation Oncology, 2017, 27, 229-239.	2.2	26
94	Verifying tumor position during stereotactic body radiation therapy delivery using (limited-arc) cone beam computed tomography imaging. Radiotherapy and Oncology, 2017, 123, 355-362.	0.6	13
95	Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nature Reviews Urology, 2017, 14, 549-563.	3.8	88
96	Stereotactic Body Radiotherapy. Medical Radiology, 2017, , 323-395.	0.1	0
97	Stereotactic body radiotherapy for de novo spinal metastases: systematic review. Journal of Neurosurgery: Spine, 2017, 27, 295-302.	1.7	121
98	The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis, 2017, 20, 217-232.	7.2	26
99	Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?. Lancet Oncology, The, 2017, 18, 566-567.	10.7	9
100	Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm. Journal of Thoracic Oncology, 2017, 12, 974-982.	1.1	42
101	Radiosurgery for epilepsy: Systematic review and International Stereotactic Radiosurgery Society (ISRS) practice guideline. Epilepsy Research, 2017, 137, 123-131.	1.6	47
102	SABR Given Thoughtfully. International Journal of Radiation Oncology Biology Physics, 2017, 99, 766.	0.8	0
103	An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. Lancet Oncology, The, 2017, 18, e720-e730.	10.7	220
104	Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review. Journal of Neurosurgery: Spine, 2017, 27, 428-435.	1.7	113
105	Stereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) Practice Guideline. Journal of Radiosurgery and SBRT, 2017, 5, 5-24.	0.2	26
106	Summary of the lecture given on June 1, 2017 on the occasion of the Jacob I. Fabrikant Award ceremony. Journal of Radiosurgery and SBRT, 2017, 5, 1-3.	0.2	0
107	Stereotactic body radiotherapy for spine and bony pelvis using flattening filter free volumetric modulated arc therapy, 6D cone-beam CT and simple positioning techniques: Treatment time and patient stability. Acta OncolA ³ gica, 2016, 55, 795-798.	1.8	12
108	Detailed evaluation of an automated approach to interactive optimization for volumetric modulated arc therapy plans. Medical Physics, 2016, 43, 1818-1828.	3.0	13

#	Article	IF	CITATIONS
109	Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer. Radiation Oncology, 2016, 11, 131.	2.7	19
110	Isotoxic radiosurgery planning for brain metastases. Radiotherapy and Oncology, 2016, 120, 253-257.	0.6	21
111	An analysis of planned versus delivered airway doses during stereotactic lung radiotherapy for central tumors. Acta Oncológica, 2016, 55, 934-937.	1.8	5
112	Subsecond and Submillimeter Resolution Positional Verification for Stereotactic Irradiation of Spinal Lesions. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1154-1162.	0.8	28
113	Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral― Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1081-1089.	1.1	176
114	A longitudinal evaluation of improvements in radiotherapy treatment plan quality for head and neck cancer patients. Radiotherapy and Oncology, 2016, 119, 337-343.	0.6	12
115	Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: Clinical validation according to the model-based approach. Radiotherapy and Oncology, 2016, 118, 298-303.	0.6	55
116	Individual patient information to select patients for different radiation techniques. European Journal of Cancer, 2016, 62, 18-27.	2.8	15
117	Prophylactic cranial irradiation for patients with lung cancer. Lancet Oncology, The, 2016, 17, e277-e293.	10.7	91
118	Technical knowâ€how in stereotactic ablative radiotherapy (<scp>SABR</scp>). Journal of Medical Radiation Sciences, 2016, 63, 5-8.	1.5	12
119	Effect of Dosimetric Outliers on the Performance of a Commercial Knowledge-Based Planning Solution. International Journal of Radiation Oncology Biology Physics, 2016, 94, 469-477.	0.8	80
120	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	1.1	156
121	Treatment and survival of second primary early-stage lung cancer, following treatment of head and neck cancer in the Netherlands. Lung Cancer, 2016, 94, 54-60.	2.0	3
122	Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis. Clinical Lung Cancer, 2016, 17, 239-244.	2.6	65
123	Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget, 2016, 7, 76613-76627.	1.8	27
124	Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Medicine, 2015, 4, 1003-1015.	2.8	29
125	Comparison of organâ€atâ€risk sparing and plan robustness for spotâ€scanning proton therapy and volumetric modulated arc photon therapy in headâ€andâ€neck cancer. Medical Physics, 2015, 42, 6589-6598.	3.0	30
126	Is there a preferred IMRT technique for leftâ€breast irradiation?. Journal of Applied Clinical Medical Physics, 2015, 16, 197-205.	1.9	34

#	Article	IF	CITATIONS
127	Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. Radiation Oncology, 2015, 10, 158.	2.7	36
128	Can knowledge-based DVH predictions be used for automated, individualized quality assurance of radiotherapy treatment plans?. Radiation Oncology, 2015, 10, 234.	2.7	103
129	Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model. International Journal of Radiation Oncology Biology Physics, 2015, 93, 82-90.	0.8	28
130	Stereotactic body radiotherapy: A survey of contemporary practice in six selected European countries. Acta Oncológica, 2015, 54, 1237-1241.	1.8	21
131	Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy. Journal of Thoracic Oncology, 2015, 10, 1195-1200.	1.1	54
132	Evaluation of a Knowledge-Based Planning Solution for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 612-620.	0.8	230
133	Parenchymal lung changes on computed tomography after stereotactic radiotherapy using high dose rate flattening filter free beams. Radiotherapy and Oncology, 2015, 114, 357-360.	0.6	1
134	Improving radiotherapy planning for large volume lung cancer: A dosimetric comparison between hybrid-IMRT and RapidArc. Acta Oncológica, 2015, 54, 427-432.	1.8	13
135	Increasing the number of arcs improves head and neck volumetric modulated arc therapy plans. Acta Oncológica, 2015, 54, 283-287.	1.8	10
136	Use of diffusion-weighted magnetic resonance imaging (DW-MRI) to investigate the effect of chemoradiotherapy on the salivary glands. Acta Oncolųgica, 2015, 54, 1068-1071.	1.8	9
137	Radiotherapy for extensive stage small-cell lung cancer – Authors' reply. Lancet, The, 2015, 385, 1292-1293.	13.7	38
138	Second primary lung cancers following a diagnosis of primary head and neck cancer. Lung Cancer, 2015, 88, 94-99.	2.0	23
139	Sub-millimeter spine position monitoring for stereotactic body radiotherapy using offline digital tomosynthesis. Radiotherapy and Oncology, 2015, 115, 223-228.	0.6	12
140	Roll and pitch set-up errors during volumetric modulated arc delivery. Strahlentherapie Und Onkologie, 2015, 191, 272-280.	2.0	5
141	Automatic interactive optimization for volumetric modulated arc therapy planning. Radiation Oncology, 2015, 10, 75.	2.7	35
142	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncology, The, 2015, 16, 630-637.	10.7	1,220
143	High-dose conventional thoracic re-irradiation for lung cancer: Updated results. Lung Cancer, 2015, 88, 235-236.	2.0	15
144	Combining radiotherapy with sunitinib: lessons (to be) learned. Angiogenesis, 2015, 18, 385-395.	7.2	32

#	Article	IF	CITATIONS
145	Patterns of long-term swallowing dysfunction after definitive radiotherapy or chemoradiation. Radiotherapy and Oncology, 2015, 117, 139-144.	0.6	72
146	Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. Radiotherapy and Oncology, 2015, 117, 64-70.	0.6	56
147	The development of stereotactic body radiotherapy in the past decade: a global perspective. Future Oncology, 2015, 11, 2721-2733.	2.4	8
148	Diagnostic challenges in survivors of early stage lung cancer. Lung Cancer, 2015, 90, 212-216.	2.0	3
149	Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. Radiotherapy and Oncology, 2015, 117, 44-48.	0.6	84
150	Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet, The, 2015, 385, 36-42.	13.7	441
151	Markerless tracking of small lung tumors for stereotactic radiotherapy. Medical Physics, 2015, 42, 1640-1652.	3.0	36
152	Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy?. Translational Lung Cancer Research, 2015, 4, 292-4.	2.8	23
153	Development and Validation of a Prediction Model for Tube Feeding Dependence after Curative (Chemo-) Radiation in Head and Neck Cancer. PLoS ONE, 2014, 9, e94879.	2.5	31
154	Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer. Radiotherapy and Oncology, 2014, 113, 95-101.	0.6	84
155	Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010. Acta Oncológica, 2014, 53, 316-323.	1.8	11
156	Toward optimal organ at risk sparing in complex volumetric modulated arc therapy: An exponential tradeâ€off with target volume dose homogeneity. Medical Physics, 2014, 41, 021722.	3.0	29
157	Investigating strategies to reduce toxicity in stereotactic ablative radiotherapy for central lung tumors. Acta OncolA³gica, 2014, 53, 330-335.	1.8	11
158	Different treatment planning protocols can lead to large differences in organ at risk sparing. Radiotherapy and Oncology, 2014, 113, 267-271.	0.6	13
159	Communicating cancer treatment information using the Web: utilizing the patient's perspective in website development. BMC Medical Informatics and Decision Making, 2014, 14, 116.	3.0	10
160	A Brief Report of 10-Year Trends in the Use of Stereotactic Lung Radiotherapy at a Dutch Academic Medical Center. Journal of Thoracic Oncology, 2014, 9, 114-117.	1.1	12
161	Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. Radiotherapy and Oncology, 2014, 112, 155-164.	0.6	140
162	Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. Radiotherapy and Oncology, 2014, 112, 165-177.	0.6	61

#	Article	IF	CITATIONS
163	Radiotherapy staffing in the European countries: Final results from the ESTRO-HERO survey. Radiotherapy and Oncology, 2014, 112, 178-186.	0.6	85
164	A clinical nomogram and recursive partitioning analysis to determine the risk of regional failure after radiosurgery alone for brain metastases. Radiotherapy and Oncology, 2014, 111, 52-58.	0.6	34
165	Patterns of distant brain recurrences after radiosurgery alone for newly diagnosed brain metastases: Implications for salvage therapy. Radiotherapy and Oncology, 2014, 112, 212-216.	0.6	25
166	Stereotactic Ablative Radiation Therapy for Subcentimeter Lung Tumors: Clinical, Dosimetric, and Image Guidance Considerations. International Journal of Radiation Oncology Biology Physics, 2014, 90, 843-849.	0.8	12
167	High-dose, conventionally fractionated thoracic reirradiation for lung tumors. Lung Cancer, 2014, 83, 356-362.	2.0	40
168	The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: A prospective cohort study. Radiotherapy and Oncology, 2014, 110, 422-428.	0.6	73
169	A Brief Report on Outcomes of Stereotactic Ablative Radiotherapy for a Second Primary Lung Cancer: Evidence in Support of Routine CT Surveillance. Journal of Thoracic Oncology, 2014, 9, 1222-1225.	1.1	14
170	Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer Journal of Clinical Oncology, 2014, 32, 7502-7502.	1.6	0
171	Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. Radiotherapy and Oncology, 2013, 109, 95-99.	0.6	55
172	The effect of induction chemotherapy on tumor volume and organ-at-risk doses in patients with locally advanced oropharyngeal cancer. Radiotherapy and Oncology, 2013, 109, 269-274.	0.6	5
173	Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiotherapy and Oncology, 2013, 107, 403-408.	0.6	46
174	Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer. Lung Cancer, 2013, 80, 62-67.	2.0	17
175	Radiotherapy capacity in Europe. Lancet Oncology, The, 2013, 14, e196-e198.	10.7	10
176	Dosimetric Impact of the Interplay Effect During Stereotactic Lung Radiation Therapy Delivery Using Flattening Filter-Free Beams and Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 743-748.	0.8	95
177	High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiotherapy and Oncology, 2013, 109, 51-57.	0.6	124
178	The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiotherapy and Oncology, 2013, 106, 370-374.	0.6	48
179	Flattening Filter Free vs Flattened Beams for Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2013, 85, 506-513.	0.8	59
180	Non-coplanar volumetric modulated arc therapy for irradiation of paranasal sinus tumors: In response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncol 2012;48(9):905–11. Oral Oncology, 2013, 49, e8.	1.5	2

#	Article	IF	CITATIONS
181	Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: A comparison of fixed-beam versus arc delivery techniques. Radiotherapy and Oncology, 2013, 109, 77-81.	0.6	27
182	Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors. Lung Cancer, 2013, 82, 95-102.	2.0	149
183	Planning of radiotherapy capacity and productivity. Radiotherapy and Oncology, 2013, 106, 266-270.	0.6	41
184	Dosimetric Impact of Intrafraction Motion During RapidArc Stereotactic Vertebral Radiation Therapy Using Flattened and Flattening Filter-Free Beams. International Journal of Radiation Oncology Biology Physics, 2013, 86, 420-425.	0.8	29
185	Comparable cell survival between high dose rate flattening filter free and conventional dose rate irradiation. Acta Oncológica, 2013, 52, 652-657.	1.8	35
186	Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review. Radiotherapy and Oncology, 2013, 106, 276-282.	0.6	237
187	RPM tracing for the detection of changes in lung tumor position: In response to Alderliesten et al. Radiother Oncol 2012;105(2):155–60. Radiotherapy and Oncology, 2013, 107, 261-262.	0.6	1
188	Frameless high dose rate stereotactic lung radiotherapy: Intrafraction tumor position and delivery time. Radiotherapy and Oncology, 2013, 107, 419-422.	0.6	36
189	Comparing rigid and deformable dose registration for high dose thoracic re-irradiation. Radiotherapy and Oncology, 2013, 106, 323-326.	0.6	21
190	Best of International Stereotactic Radiosurgery Society Congress 2013: stereotactic body radiation therapy. Part I: spinal tumors. Future Oncology, 2013, 9, 1299-1302.	2.4	3
191	Best of International Stereotactic Radiosurgery Society Congress 2013: stereotactic body radiation therapy. Part II: nonspinal tumors. Future Oncology, 2013, 9, 1303-1306.	2.4	2
192	Radiotherapy capacity in Europe—time to even things out?. Nature Reviews Clinical Oncology, 2013, 10, 188-190.	27.6	3
193	Bowel-sparing intensity-modulated radiotherapy (IMRT) for palliation of large-volume pelvic bone metastases: Rationale, technique and clinical implementation. Acta OncolA3gica, 2013, 52, 877-880.	1.8	5
194	Stage l–ll non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Annals of Oncology, 2013, 24, 1543-1548.	1.2	261
195	Digital tomosynthesis for verifying spine position during radiotherapy: a phantom study. Physics in Medicine and Biology, 2013, 58, 5717-5733.	3.0	12
196	Digital tomosynthesis (DTS) for verification of target position in early stage lung cancer patients. Medical Physics, 2013, 40, 091904.	3.0	14
197	Blinded assessment of radiological changes after stereotactic ablative radiotherapy (SABR) for early-stage lung cancer: Local recurrences versus fibrosis Journal of Clinical Oncology, 2013, 31, 7520-7520.	1.6	3
198	Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes. Journal of Thoracic Disease, 2013, 5, 116-22.	1.4	29

#	Article	IF	CITATIONS
199	Cone-beam computed tomography imaging in stereotactic body radiotherapy allows for more than target localization. Journal of Radiosurgery and SBRT, 2013, 2, 141-145.	0.2	1
200	Primary Lung Cancer. Medical Radiology, 2012, , 137-162.	0.1	2
201	Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands. Annals of Oncology, 2012, 23, 2743-2747.	1.2	147
202	Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1148-1154.	1.1	105
203	Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 348-353.	0.8	324
204	Proton Stereotactic Body Radiation Therapy for Clinically Challenging Cases of Centrally and Superiorly Located Stage I Non-Small-Cell Lung Cancer: In Regards to Register et al. Int J Radiat Oncol Biol Phys 2011;80:1015–1022 International Journal of Radiation Oncology Biology Physics, 2012, 82, 492.	0.8	3
205	Fast Arc Delivery for Stereotactic Body Radiotherapy of Vertebral and Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 83, e137-e143.	0.8	71
206	Clinical Application of a Novel Hybrid Intensity-Modulated Radiotherapy Technique for StageÂIII Lung Cancer and Dosimetric Comparison WithÂFour Other Techniques. International Journal of Radiation Oncology Biology Physics, 2012, 83, e297-e303.	0.8	42
207	Feasibility of using anatomical surrogates for predicting the position of lung tumours. Radiotherapy and Oncology, 2012, 102, 287-289.	0.6	6
208	Predictive modelling for swallowing dysfunction after primary (chemo)radiation: Results of a prospective observational study. Radiotherapy and Oncology, 2012, 105, 107-114.	0.6	223
209	A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases. Radiotherapy and Oncology, 2012, 102, 180-186.	0.6	35
210	An analysis of patient positioning during stereotactic lung radiotherapy performed without rigid external immobilization. Radiotherapy and Oncology, 2012, 104, 28-32.	0.6	37
211	Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. BMC Cancer, 2012, 12, 305.	2.6	207
212	Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncology, The, 2012, 13, 802-809.	10.7	416
213	Combining angiogenesis inhibition and radiotherapy: A double-edged sword. Drug Resistance Updates, 2012, 15, 173-182.	14.4	60
214	Implementing new radiotherapy techniques. British Journal of Health Care Management, 2012, 18, 266-271.	0.2	0
215	Normal Tissue Constraints. Medical Radiology, 2012, , 393-410.	0.1	Ο
216	Valproic acid sensitizes human glioma cells for temozolomide and Î ³ -radiation. Journal of Neuro-Oncology, 2012, 107, 61-67.	2.9	92

#	Article	IF	CITATIONS
217	Stages I-II non-small cell lung cancer treated using either lobectomy by video-assistedÂthoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis Journal of Clinical Oncology, 2012, 30, 7009-7009.	1.6	5
218	An evaluation of websites providing patient information on stereotactic body radiation therapy (SBRT) for stage I lung cancer in three Western European countries. Journal of Radiosurgery and SBRT, 2012, 1, 303-315.	0.2	0
219	Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: Comparison with a contemporaneous cohort with pathologically proven disease. Radiotherapy and Oncology, 2011, 101, 250-254.	0.6	128
220	Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiotherapy and Oncology, 2011, 101, 240-244.	0.6	157
221	Imaging for Stereotactic Spine Radiotherapy: Clinical Considerations. International Journal of Radiation Oncology Biology Physics, 2011, 81, 321-330.	0.8	35
222	Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 2036-2043.	1.1	237
223	Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1221-1228.	1.1	151
224	Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 2052-2057.	1.1	97
225	Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy. Radiation Oncology, 2011, 6, 74.	2.7	20
226	Time for reappraisal of extracranial treatment options?. Cancer, 2011, 117, 597-605.	4.1	17
227	RapidArc Planning and Delivery in Patients With Locally Advanced Head-and-Neck Cancer Undergoing Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 429-435.	0.8	76
228	Dosimetric Impact of Interplay Effect on RapidArc Lung Stereotactic Treatment Delivery. International Journal of Radiation Oncology Biology Physics, 2011, 79, 305-311.	0.8	102
229	Radiotherapy in Small-Cell Lung Cancer: Lessons Learned and Future Directions. International Journal of Radiation Oncology Biology Physics, 2011, 79, 998-1003.	0.8	34
230	Impact of the calculation resolution of AAA for small fields and RapidArc treatment plans. Medical Physics, 2011, 38, 4471-4479.	3.0	43
231	Compromised Health-Related Quality of Life in Patients With Low-Grade Glioma. Journal of Clinical Oncology, 2011, 29, 4430-4435.	1.6	160
232	Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells. International Journal of Radiation Biology, 2011, 87, 192-201.	1.8	3
233	Stereotactic body radiotherapy for stage I non-small cell lung cancer. Journal of Radiosurgery and SBRT, 2011, 1, 63-69.	0.2	0
234	Volumetric Modulated Arc Therapy for Advanced Pancreatic Cancer. Strahlentherapie Und Onkologie, 2010, 186, 382-387.	2.0	39

#	Article	IF	CITATIONS
235	Ipsilateral Irradiation for Oral and Oropharyngeal Carcinoma Treated With Primary Surgery and Postoperative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 682-688.	0.8	47
236	Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. Journal of Neuro-Oncology, 2010, 97, 89-94.	2.9	71
237	Stage I nonsmall cell lung cancer in patients aged ≥75 years. Cancer, 2010, 116, 406-414.	4.1	177
238	In Reply to Dr. Bauman. International Journal of Radiation Oncology Biology Physics, 2010, 78, 965.	0.8	0
239	Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. British Journal of Cancer, 2010, 103, 29-35.	6.4	89
240	Clinical Investigations Original article Patterns of care study for brachytherapy: results of the questionnaire for the years 2002 and 2007 in The Netherlands. Journal of Contemporary Brachytherapy, 2010, 4, 145-152.	0.9	5
241	Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis. Journal of Clinical Oncology, 2010, 28, 5153-5159.	1.6	434
242	Stereotactic radiation therapy for large vestibular schwannomas. Radiotherapy and Oncology, 2010, 95, 94-98.	0.6	42
243	Clinical outcome after repeated radiosurgery for brain arteriovenous malformations. Radiotherapy and Oncology, 2010, 95, 250-256.	0.6	22
244	Improving target delineation on 4-dimensional CT scans in stage I NSCLC using a deformable registration tool. Radiotherapy and Oncology, 2010, 96, 67-72.	0.6	63
245	A novel simple approach for incorporation of respiratory motion in stereotactic treatments of lung tumors. Radiotherapy and Oncology, 2010, 97, 443-448.	0.6	11
246	The accuracy of frameless stereotactic intracranial radiosurgery. Radiotherapy and Oncology, 2010, 97, 390-394.	0.6	68
247	Stereotactic radiotherapy for peripheral lung tumors: A comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiotherapy and Oncology, 2010, 97, 437-442.	0.6	191
248	Treatment of large stage l–II lung tumors using stereotactic body radiotherapy (SBRT): Planning considerations and early toxicity. Radiotherapy and Oncology, 2010, 97, 431-436.	0.6	127
249	Strategies for the analysis of in vitro radiation sensitivity and prediction of interaction with potential radiation modifying agents. International Journal of Radiation Biology, 2010, 86, 458-466.	1.8	6
250	Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms—Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups. Journal of Clinical Oncology, 2009, 27, 78-84.	1.6	240
251	Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurology, The, 2009, 8, 810-818.	10.2	598
252	Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer, 2009, 115, 587-594.	4.1	61

#	Article	IF	CITATIONS
253	Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. Journal of Neurology, 2009, 256, 878-887.	3.6	137
254	Volumetric Modulated Arc Radiotherapy for Vestibular Schwannomas. International Journal of Radiation Oncology Biology Physics, 2009, 74, 610-615.	0.8	82
255	Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 389-395.	6.4	71
256	Intensity-Modulated Radiotherapy Reduces Radiation-Induced Morbidity and Improves Health-Related Quality of Life: Results of a Nonrandomized Prospective Study Using a Standardized Follow-Up Program. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1-8.	0.8	280
257	Role of Adaptive Radiotherapy During Concomitant Chemoradiotherapy for Lung Cancer: Analysis of Data From a Prospective Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1092-1097.	0.8	32
258	Volumetric Intensity-Modulated Arc Therapy Vs. Conventional IMRT in Head-and-Neck Cancer: A Comparative Planning and Dosimetric Study. International Journal of Radiation Oncology Biology Physics, 2009, 74, 252-259.	0.8	382
259	An Evaluation of Two Internal Surrogates for Determining the Three-Dimensional Position of Peripheral Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2009, 74, 623-629.	0.8	10
260	Whole-Brain Radiotherapy With Simultaneous Integrated Boost to Multiple Brain Metastases Using Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 253-259.	0.8	96
261	Radiotherapy for lung cancer: Clinical impact of recent technical advances. Lung Cancer, 2009, 64, 1-8.	2.0	41
262	Health-related quality of life of long-term high-grade glioma survivors. Neuro-Oncology, 2009, 11, 51-58.	1.2	70
263	A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiotherapy and Oncology, 2009, 90, 189-195.	0.6	178
264	Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiotherapy and Oncology, 2009, 93, 122-124.	0.6	154
265	Radiosurgery of brain arteriovenous malformations in children. Journal of Neurology, 2008, 255, 551-560.	3.6	40
266	Evaluation of Four-Dimensional Computed Tomography-Based Intensity-Modulated and Respiratory-Gated Radiotherapy Techniques for Pancreatic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1215-1220.	0.8	46
267	Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 70, 685-692.	0.8	510
268	Analysis of Carina Position as Surrogate Marker for Delivering Phase-Gated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1111-1117.	0.8	27
269	Impact of Audio-Coaching on the Position of Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1118-1123.	0.8	35
270	Analysis of reproducibility of respiration-triggered gated radiotherapy for lung tumors. Radiotherapy and Oncology, 2008, 87, 59-64.	0.6	30

#	Article	IF	CITATIONS
271	Palliative-care trials: how best to publish findings?. Lancet Oncology, The, 2008, 9, 411-412.	10.7	2
272	Tumor-Volume Changes after Radiosurgery for Vestibular Schwannoma: Implications for Follow-Up MR Imaging Protocol. American Journal of Neuroradiology, 2008, 29, 906-910.	2.4	77
273	Impact of Late Treatment-Related Toxicity on Quality of Life Among Patients With Head and Neck Cancer Treated With Radiotherapy. Journal of Clinical Oncology, 2008, 26, 3770-3776.	1.6	569
274	Critical Review of Nonsurgical Treatment Options for Stage I Non‧mall Cell Lung Cancer. Oncologist, 2008, 13, 309-319.	3.7	57
275	LINEAR ACCELERATOR-BASED STEREOTACTIC RADIOSURGERY FOR BILATERAL VESTIBULAR SCHWANNOMAS IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2. Neurosurgery, 2008, 62, A37-A43.	1.1	27
276	Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: Independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. International Journal of Radiation Biology, 2007, 83, 677-685.	1.8	38
277	COLOR INTENSITY PROJECTION OF DIGITALLY SUBTRACTED ANGIOGRAPHY FOR THE VISUALIZATION OF BRAIN ARTERIOVENOUS MALFORMATIONS. Neurosurgery, 2007, 60, 511-515.	1.1	25
278	Can Mediastinal Nodal Mobility Explain the Low Yield Rates for Transbronchial Needle Aspiration Without Real-Time Imaging?. Chest, 2007, 131, 1783-1787.	0.8	33
279	Unilateral versus bilateral irradiation in squamous cell head and neck cancer in relation to patient-rated xerostomia and sticky saliva. Radiotherapy and Oncology, 2007, 85, 83-89.	0.6	59
280	The course of neurocognitive functioning in high-grade glioma patients1. Neuro-Oncology, 2007, 9, 53-62.	1.2	153
281	Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. New England Journal of Medicine, 2007, 357, 664-672.	27.0	990
282	D1-01: Prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer (ED-SCLC) after response to chemotherapy (EORTC 08993-22993): Quality of life (QoL) results Journal of Thoracic Oncology, 2007, 2, S389.	1.1	1
283	B5-04: Clinical results and toxicity after 4-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, S348.	1.1	4
284	Delineation of brain AVMs on MR-Angiography for the purpose of stereotactic radiosurgery. International Journal of Radiation Oncology Biology Physics, 2007, 67, 308-316.	0.8	20
285	Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. International Journal of Radiation Oncology Biology Physics, 2007, 67, 775-780.	0.8	102
286	Is Adaptive Treatment Planning Required for Stereotactic Radiotherapy of Stage I Non–Small-Cell Lung Cancer?. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1370-1374.	0.8	54
287	Impact of Radiation-Induced Xerostomia on Quality of Life After Primary Radiotherapy Among Patients With Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 751-760.	0.8	190
288	A Four-Dimensional CT-Based Evaluation of Techniques for Gastric Irradiation. International Journal of Radiation Oncology Biology Physics, 2007, 69, 903-909.	0.8	37

#	Article	IF	CITATIONS
289	Differential Radiosensitizing Potential of Temozolomide in MGMT Promoter Methylated Glioblastoma Multiforme Cell Lines. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1246-1253.	0.8	59
290	Verifying 4D gated radiotherapy using time-integrated electronic portal imaging: a phantom and clinical study. Radiation Oncology, 2007, 2, 32.	2.7	14
291	Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. Journal of Neuro-Oncology, 2007, 85, 25-31.	2.9	27
292	Monitoring Response to Radiotherapy in Human Squamous Cell Cancer Bearing Nude Mice: Comparison of 2′-deoxy-2′-[18F]fluoro-d-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT). Molecular Ima and Biology, 2007, 9, 340-347.	ging	43
293	Re-irradiation of a second localization of idiopathic midline destructive disease in the head and neck area. European Archives of Oto-Rhino-Laryngology, 2007, 264, 1521-1523.	1.6	3
294	4D imaging for target definition in stereotactic radiotherapy for lung cancer. Acta Oncológica, 2006, 45, 966-972.	1.8	74
295	A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiotherapy and Oncology, 2006, 78, 306-312.	0.6	85
296	Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation. Radiotherapy and Oncology, 2006, 79, 39-44.	0.6	36
297	Evaluating mobility for radiotherapy planning of lung tumors: A comparison of virtual fluoroscopy and 4DCT. Lung Cancer, 2006, 53, 31-37.	2.0	28
298	Reproducibility of target volumes generated using uncoached 4-dimensional CT scans for peripheral lung cancer. Radiation Oncology, 2006, 1, 43.	2.7	31
299	A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. Radiation Oncology, 2006, 1, 8.	2.7	51
300	Renal mobility during uncoached quiet respiration: An analysis of 4DCT scans. International Journal of Radiation Oncology Biology Physics, 2006, 64, 799-803.	0.8	57
301	Time trends in target volumes for stage I non–small-cell lung cancer after stereotactic radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1221-1228.	0.8	60
302	The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1323-1329.	0.8	25
303	The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncology, 2006, 42, 131-138.	1.5	40
304	Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer, 2006, 106, 1536-1547.	4.1	70
305	Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly. Cancer, 2006, 107, 544-553.	4.1	45
306	Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: recurrence or second primary tumor?. Journal of Neurosurgery, 2006, 105, 739-744.	1.6	16

#	Article	IF	CITATIONS
307	Stereotactic radiosurgery for brain AVMs: Role of interobserver variation in target definition on digital subtraction angiography. International Journal of Radiation Oncology Biology Physics, 2005, 62, 246-252.	0.8	50
308	Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: An analysis of 4DCT datasets. International Journal of Radiation Oncology Biology Physics, 2005, 62, 554-560.	0.8	192
309	Use of CD-ROM–based tool for analyzing contouring variations in involved-field radiotherapy for Stage III NSCLC. International Journal of Radiation Oncology Biology Physics, 2005, 63, 334-339.	0.8	18
310	Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 253-260.	0.8	270
311	Riskâ€group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer, 2005, 104, 1408-1417.	4.1	122
312	Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. International Journal of Radiation Oncology Biology Physics, 2005, 61, 392-399.	0.8	35
313	Effects of irradiation and cisplatin on human glioma spheroids: inhibition of cell proliferation and cell migration. Journal of Cancer Research and Clinical Oncology, 2005, 131, 723-732.	2.5	24
314	Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. Journal of Cancer Research and Clinical Oncology, 2005, 131, 653-661.	2.5	24
315	Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: Work package 1. Radiotherapy and Oncology, 2005, 75, 349.E1-349.E6.	0.6	148
316	Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiotherapy and Oncology, 2005, 75, 355-365.	0.6	202
317	Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?. Radiotherapy and Oncology, 2005, 77, 164-171.	0.6	116
318	Influence of anoxia on the induction of mutations by phenylalanine radicals during γ-irradiation of plasmid DNA in aqueous solution. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 568, 171-177.	1.0	0
319	Radiotherapy of squamous cell carcinoma of the nasal vestibule. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1319-1325.	0.8	54
320	Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1283-1290.	0.8	277
321	Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer Research, 2004, 24, 2511-4.	1.1	24
322	Infrastructure of radiotherapy in the Netherlands: evaluation of prognoses and introduction of a new model for determining the needs. Radiotherapy and Oncology, 2003, 66, 345-349.	0.6	39
323	The importance of pre-treatment haemoglobin level in inoperablenon-small cell lung carcinoma treated with radical radiotherapy. Radiotherapy and Oncology, 2003, 67, 321-325.	0.6	30
324	Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch–Belgian survey. Radiotherapy and Oncology, 2003, 68, 299-302.	0.6	30

#	Article	IF	CITATIONS
325	The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Molecular Imaging and Biology, 2003, 5, 257-270.	2.6	37
326	Thallium-201 Single-Photon Emission Computed Tomography As an Early Predictor of Outcome in Recurrent Glioma. Journal of Clinical Oncology, 2003, 21, 3559-3565.	1.6	44
327	Past, current and future protocols for combined modality therapy in childhood medulloblastoma. Expert Review of Anticancer Therapy, 2003, 3, 79-90.	2.4	5
328	Oxygenation and response to irradiation of organotypic multicellular spheroids of human glioma. Anticancer Research, 2003, 23, 1461-6.	1.1	17
329	Matching PET and CT scans of the head and neck area: Development of method and validation. Medical Physics, 2002, 29, 2230-2238.	3.0	29
330	Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet, The, 2002, 360, 1361-1368.	13.7	572
331	Re-Irradiation of the Human Spinal Cord. Strahlentherapie Und Onkologie, 2002, 178, 453-456.	2.0	30
332	Radiosensitivity and TP53, EGFR Amplification and LOH10 Analysis of Primary Glioma Cell Cultures. Strahlentherapie Und Onkologie, 2002, 178, 491-496.	2.0	10
333	Quality of life after curative radiotherapy in Stage I non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 847-853.	0.8	28
334	Radiation therapy in early stage Hodgkin's disease: long-term results and adverse effects. The Hematology Journal, 2002, 3, 179-184.	1.4	4
335	External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiotherapy and Oncology, 2001, 58, 257-268.	0.6	94
336	Reirradiation of primary brain tumours: survival, clinical response and prognostic factors. Radiotherapy and Oncology, 2001, 59, 127-137.	0.6	103
337	The efficacy of Xialine® in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiotherapy and Oncology, 2001, 59, 157-160.	0.6	55
338	The importance of using absolute mutant frequencies to compare mutation spectra. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 479, 95-99.	1.0	4
339	Squamous cell carcinoma of maxillary sinus. , 2000, 22, 164-169.		77
340	Positive surgical margins in neck dissection specimens in patients with head and neck squamous cell carcinoma and the effect of radiotherapy. Head and Neck, 2000, 22, 559-563.	2.0	32
341	Survival of human glioma cells treated with various combination of temozolomide and X-rays. International Journal of Radiation Oncology Biology Physics, 2000, 47, 779-784.	0.8	133
342	Mutagenic effect by phenylalanine during γ-irradiation of plasmid DNA in aqueous solution under oxic conditions. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000, 454, 71-76.	1.0	3

#	Article	IF	CITATIONS
343	The role of nucleotide excision repair of Escherichia coli in repair of spontaneous and gamma-radiation-induced DNA damage in the lacZα gene. Mutation Research DNA Repair, 2000, 460, 117-125.	3.7	8
344	The influence of combined Fpg- and MutY-deficiency on the spontaneous and γ-radiation-induced mutation spectrum in the lacZl± gene of M13mp10. Mutation Research DNA Repair, 2000, 461, 189-195.	3.7	12
345	Effect of CT-based treatment planning on portal field size and outcome in radiation treatment of localized prostate cancer. Radiotherapy and Oncology, 2000, 55, 27-30.	0.6	3
346	Local radiation dose, fixation, and non-union of mandibulotomies. , 1999, 21, 315-318.		16
347	The influence of formamidopyrimidine-DNA glycosylase on the spontaneous and Î ³ -radiation-induced mutation spectrum of the lacZα gene. Mutation Research DNA Repair, 1999, 435, 141-150.	3.7	12
348	Radiosensitizing effect of cisplatin in prostate cancer cell lines. Cancer Letters, 1996, 101, 233-239.	7.2	17
349	Hypofractionated radiation therapy in patients with glioblastoma multiforme: Results of treatment and impact of prognostic factors. International Journal of Radiation Oncology Biology Physics, 1996, 34, 895-898.	0.8	60
350	Importance of timing of radiotherapy in breast conserving treatment for early stage breast cancer. Radiotherapy and Oncology, 1994, 30, 206-212.	0.6	94
351	Correlation between nuclear DNA content and steroid receptor status in ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1991, 38, 221-227.	1.1	10
352	Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer, 1990, 66, 740-744.	4.1	48
353	Response to inhibition of androgen action of human ovarian cancer cells in vitro. Cancer Letters, 1989, 45, 213-220.	7.2	31
354	Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: High tumor progesterone receptor levels correlate with longer survival. Gynecologic Oncology, 1989, 33, 76-81.	1.4	52